首站-论文投稿智能助手
典型文献
Relapse after CAR-T cell therapy in B-cell malignancies:challenges and future approaches
文献摘要:
Chimeric antigen receptor-T (CAR-T) cell therapy, as a novel cellular immunotherapy, has dramatically reshaped the landscape of cancer treatment, especially in hematological malignancies. However, relapse is still one of the most troublesome obstacles to achieving broad clinical application. The intrinsic factors and superior adaptability of tumor cells mark a fundamental aspect of relapse. The unique biological function of CAR-T cells governed by their special CAR construction also affects treatment efficacy. Moreover, complex cross-interactions among CAR-T cells, tumor cells, and the tumor microenvironment (TME) profoundly influence clinical outcomes concerning CAR-T cell function and persistence. Therefore, in this review, based on the most recent discoveries, we focus on the challenges of relapse after CAR-T cell therapy in B-cell malignancies from the perspective of tumor cells, CAR-T cells, and the TME. We also discuss the corresponding basic and clinical approaches that may overcome the problem in the future. We aim to provide a comprehensive understanding for scientists and physicians that will help improve research and clinical practice.
文献关键词:
作者姓名:
Tianning GU;Meng ZHU;He HUANG;Yongxian HU
作者机构:
Bone Marrow Transplantation Center,the First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China;Liangzhu Laboratory,Zhejiang University Medical Center,Hangzhou 311121,China;Institute of Hematology,Zhejiang University,Hangzhou 310058,China;Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy,Hangzhou 310058,China
引用格式:
[1]Tianning GU;Meng ZHU;He HUANG;Yongxian HU-.Relapse after CAR-T cell therapy in B-cell malignancies:challenges and future approaches)[J].浙江大学学报(英文版)(B辑:生物医学和生物技术),2022(10):793-811
A类:
Relapse
B类:
after,CAR,malignancies,challenges,future,approaches,Chimeric,antigen,receptor,novel,cellular,immunotherapy,has,dramatically,reshaped,landscape,cancer,treatment,especially,hematological,However,relapse,still,one,most,troublesome,obstacles,achieving,broad,clinical,application,intrinsic,factors,superior,adaptability,tumor,cells,mark,fundamental,aspect,unique,biological,function,governed,by,their,construction,also,affects,efficacy,Moreover,complex,cross,interactions,among,microenvironment,TME,profoundly,influence,outcomes,concerning,persistence,Therefore,this,review,recent,discoveries,focus,from,perspective,We,discuss,corresponding,basic,that,may,overcome,problem,aim,provide,comprehensive,understanding,scientists,physicians,will,help,improve,research,practice
AB值:
0.602238
相似文献
Systematic screening reveals synergistic interactions that overcome MAPK inhibitor resistance in cancer cells
Yu Yu;Minzhen Tao;Libin Xu;Lei Cao;Baoyu Le;Na An;Jilin Dong;Yajie Xu;Baoxing Yang;Wei Li;Bing Liu;Qiong Wu;Yinying Lu;Zhen Xie;Xiaohua Lian-Department of Cell Biology,Basic Medical College,Army Medical University(Third Military Medical University),Chongqing 400038,China;MOE Key Laboratory of Bioinformatics and Bioinformatics Division,Center for Synthetic and System Biology,Department of Automation,Beijing National Research Center for Information Science and Technology,Tsinghua University,Beijing 100084,China;National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Thoracic Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Beijing 100730,China;Beijing Syngentech Co.,Ltd,Beijing 102206,China;School of Life Sciences,Tsinghua University,Beijing 100084,China;The Comprehensive Liver Cancer Center,The 5th Medical Center of PLA General Hospital,Beijing 100039,China
Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies:a phase I clinical study
Yongxian Hu;Yali Zhou;Mingming Zhang;Houli Zhao;Guoqing Wei;Wengang Ge;Qu Cui;Qitian Mu;Gong Chen;Lu Han;Tingting Guo;Jiazhen Cui;Xiaoyan Jiang;Xiujun Zheng;Shuhui Yu;Xiaolong Li;Xingwang Zhang;Mingxi Chen;Xiuju Li;Ming Gao;Kang Wang;Cheng Zu;Hao Zhang;Xiaohong He;Yanbin Wang;Dongrui Wang;Jiangtao Ren;He Huang-Bone Marrow Transplantation Center,The First Affiliated Hospital,School of Medicine,Zhejiang University,Hangzhou,Zhejiang,China;Liangzhu Laboratory,Zhejiang University Medical Center,Hangzhou,Zhejiang,China;Institute of Hematology,Zhejiang University,Hangzhou,Zhejiang,China;Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy,Hangzhou,Zhejiang,China;Nanjing Bioheng Biotech Co.,Ltd,Nanjing,Jiangsu,China;Department of Hematology,Ruian people's Hospital,Wenzhou,Zhejiang,China;Department of Hematology,Beijing Tiantan Hospital,Capital Medical University Beijing China;Laboratory of Stem Cell Transplantation Ningbo First Hospital Ningbo,Zhejiang,China
Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo
Fanxiang Yin;Ran Zhao;Dhilli Rao Gorja;Xiaorong Fu;Ning Lu;Hai Huang;Beibei Xu;Hanyong Chen;Jung-Hyun Shim;Kangdong Liu;Zhi Li;Kyle Vaughn Laster;Zigang Dong;Mee-Hyun Lee-Department of Pathophysiology,School of Basic Medical Sciences,Zhengzhou University,Zhengzhou 450001,China;China-US(Henan)Hormel Cancer Institute,Zhengzhou 450008,China;Translational Medical Center,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;The Hormel Institute,University of Minnesota,Austin,MN 55912,USA;Department of Biomedicine,Health&Life Convergencen Science,BK21 Four,College of Pharmacy,Mokpo National University,Jeonnam 58554,Republic of Korea;The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention,Zhengzhou 450001,China;Department of General Surgery,the Affiliated Tumor Hospital of Zhengzhou University,Zhengzhou 450008,China;College of Korean Medicine,Dongshin University,Naju 58245,Republic of Korea
Acquisition of taxane resistance by p53 inactivation in ovarian cancer cells
Changfa Shu;Xi Zheng;Alafate Wuhafu;Danielle Cicka;Sean Doyle;Qiankun Niu;Dacheng Fan;Kun Qian;Andrey A.Ivanov;Yuhong Du;Xiulei Mo;Haian Fu-Department of Pharmacology and Chemical Biology,Emory University School of Medicine,Atlanta,GA 30322,USA;Department of Gynecology and Obstetrics,The Third Xiangya Hospital of Central South University,Changsha 410013,China;Cancer Institute,the Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310052,China;The First Affiliated Hospital,Medical School of Xi'an Jiaotong University,Xi'an 710061,China;Emory Chemical Biology Discovery Center,Emory University School of Medicine,Atlanta,GA 30322,USA;Department of Hematology and Medical Oncology and Winship Cancer Institute,Emory University,Atlanta,GA 30322,USA
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。